Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Over $2 today, short covering big buyers 900K bought in 2 blocks yesterday last half of the day. With the volume this stock has and the liquidity , it makes it very appealing!
Surgeons buying or doctors groups buying
I did to bought 500,000...love it!!
The huge volume will bring in the big boys!
The huge volume will bring in the big boys!
ALZM is in Gold & Silver exploration too?...great market now!
Yes, big block of shares being bought!
bid 1.64 X 1.65 were going up..shorts covering
Wow, you hit the nail right on the head Tophats! I am in the healthcare industry and see the need and demand for this company.
Got the ad a week ago..we still have room to run with this.
Thank you all for your information. This is going to get very exciting in the coming months! Great company and great product!
I'm a Doctor seeing the need for this! I'm in long!!
Allezoe Medical Holdings is poised to solve one of the biggest medical problems in the world – the 65% wastage of all organs donated for transplant!
That’s why I say ALZM is my #1 Buyout Target of the medical giants I mentioned earlier. It’s clearly one of the biggest profit opportunities of the decade, with fast 10x, 20x, even 30x profit potential!
http://www2.smallcapfortunes.com/alzm/index.html
By dramatically improving the health, quality, and number of organs for transplant, Allezoe Medical (ALZM on the OTCBB exchange) will expand the current $3 billion “organ procurement market” to $6 billion, and then totally dominate it!
But of even more importance to investors... because Allezoe’s revolutionary technology will stop the terrible waste of donor organs and vastly increase the number of successful transplants...
The TOTAL organ transplant market will jump from $21 billion to $60 billion.
advertisement, see disclaimer at bottom
Allezoe Medical expands
the total market by $40 billion!
And that’s what makes ALZM my #1 BUYOUT TARGET of at least a dozen medical giants, who will see the Allezoe acquisition as essential to their growth!
The only possible result I can see from this “transformational event” is that ALZM shares will jump 10, 20, even 30 times higher. And here are the facts to back me up...
Few people know the real reason for the
extremely low organ-transplant success rate
(a huge problem ALZM solves)
This blockbuster investment opportunity starts with this little- known fact.
Tragically, the rest die waiting or get too old or sick to stay on the waitlist. And yet, this 35% overall success rate is heartbreakingly deceiving because...
If all the people who truly need an organ could “get on the waitlist,” the list would be 3 times larger. Meaning the real success rate is only 12%.
For humane reasons the waitlist is severely restricted to just the top candidates, because giving false hope to 88% of all patients is deemed morally unacceptable.
But now the Allezoe technology will eventually make it possible to put everybody in need on the waitlist, and then provide up to 80% fulfillment!
Excited? I sure am! ALZM is a fortune-making opportunity for early shareholders. Just think...
We’re talking about expanding a $21 billion market to $60 billion, and just one little company has the “proven technology” to make the whole thing happen!
But you may be wondering: Why is the transplant success rate so low?
It’s not so much a shortage of donors (more people are signing up for organ donation all the time). Nor is it a lack of talented surgical teams. Nor even a lack of funding...
The biggest problem is that two-thirds of all donated organs are wasted because of the primitive preservation and transportation technology that damages or kills the organs in transit.
Allezoe Medical solves this problem and it does so with a revolutionary new technology that’s a GIANT LEAP forward...
In fact, the firm’s technology is so advanced that there is practically NO SECOND PLACE (all the better for us while we can still get ALZM shares under $2).
Check this amazing advance.
Yes, 6 times longer, expanding the current 3 to 4 hour transplant window to 20 to 24 hours. And in many cases, the ALZM system will actually resuscitate and improve the health of the organ in transit (more on this ahead).
This ADVANCE will eliminate the tragic 65% wastage, make vastly more healthy organs available for transplant, and significantly reduce costs by removing “procurement” from an emergency-based system.
That’s why I’m convinced, early ALZM shareholders will see their shares climb 5 to 10 times higher, and then double or triple again during the inevitable bidding war (see the potential big-name buyers just ahead).
Hi, I’m Eric Dickson, editor of Breakaway Stocks, the advisory letter for investors seeking fortune-making gains from game- changing companies. In my report today, I’m going to give you all of the decision- making facts...
And the first thing to grasp about the organ transplant industry is...
The biggest enemy is
“time” and ALZM increases
the time 6-fold!
For example, using the current standard-of- care technology, donor hearts survive just 3 to 4 hours. Of this, 2 hours are needed for the harvesting and transplant operations, leaving just a 1 to 2 hour window for transport to the waiting patient.
How far can you take a heart in just an hour or two? Sadly, 73% of all donor hearts die or become too damaged to use because of today’s crude preservation technology that simply puts the heart in a plastic bag on ice in a picnic cooler.
I’m not kidding! And I’m sure you’ve seen news footage or a TV drama, showing an emergency medical team running to the helicopter with the Igloo cooler in hand.
But here’s the blockbuster change the ALZM technology will now bring...
The Life Cradle™ System not only preserves the heart (or other organ) but oxygenates, nourishes, and resuscitates it during transit. A built-in computer also continually monitors its life signs, so the surgeon receives a computerized “health status” report upon its arrival.
The extraordinary ramifications of this breakthrough will become crystal clear as we continue, but rest assured you’re getting advance notice on one of the BIGGEST profit opportunities of the decade!
advertisement, see disclaimer at bottom
ALZM eliminates all of the worst problems
and adds several big benefits
When ALZM adds 18 to 22 hours to the “transplant viability window,” a host of serious problems are eliminated, including...
Surgeon guesswork regarding the organ’s health!
Poor donor-to-recipient matches due to short viability time!
High risks added by damaged organs and rushed conditions!
High labor and transport costs due to emergency system!
No time for pre-op testing to help ensure a good outcome!
The amazing Life Cradle™ System converts every one of the above problems into a benefit for two reasons — added “time” and a healthy, nourishing transport system. But here’s another benefit you probably didn’t think of... Because extreme urgency is eliminated, the Life Cradle™ can fly on regularly scheduled commercial flights to any location on the continent (here or abroad).
The unit is designed to buckle into a normal passenger seat, which eliminates the need for high-priced aircraft and expensive emergency flight and medical crews, which under the current very costly “emergency system” are maintained on standby.
From an investment viewpoint... ALZM’s revolutionary advance will make hundreds of thousands more “healthy organs” available for transplant. It will immediately put ALZM on top of a $6 billion procurement market. And it’ll expand the overall transplant market from $21 billion to $60 billion!
This is a recipe to dramatically enrich early ALZM shareholders!
Just ahead, I’ll show you the company’s amazing technology, and why a 2,000% profit score may be “too conservative,” considering how valuable this company will be to several medical giants...
But first, let me give you a handful of key facts that should have you racing to your online trading account to acquire Allezoe Medical shares (symbol ALZM on the OTCBB exchange). Consider that...
The Life Cradle™ System has been...
Developed through 7 generations of prototypes with constant input and feedback from the top organ transplant centers in America and Europe!
Completely tested in 225 preservation experiments–all successful and many producing results beyond anyone’s wildest expectations!
Proved in both concept and real-life animal studies, with dozens of peer-reviewed articles published in leading medical journals!
Sought out by major medical universities and transplant centers across America and Europe for important studies and the imminent clinical approval trials (on a favored fast-track status)!
And most important to investors... ALZM has insurmountable patent protections (4 issued and 4 pending) as well as the enthusiastic backing of the most important figures in the organ transplant industry.
The biggest names in “organ transplant”
are enthusiastically backing ALZM
No less than the illustrious former Wisconsin Governor and Health & Human Services Secretary, Tommy Thompson, is on the ALZM corporate board...
Secretary Thompson has been a tireless promoter for “more organ donations” and was instrumental in establishing the Organ Donation Breakthrough Collaborative, which has resulted in a dramatic increase in donated organs in recent years.
Secretary Thompson enthusiastically joined the ALZM board when he realized the biggest problem wasn’t a serious lack of organ donors, but a serious lack of technology to preserve the organs in transit. Again, two-thirds of all organs are wasted, and 73% of all hearts!
Also on the ALZM boards...
The distinguished Dr. Robert Kormos, former president of the International Society for Heart and Lung Transplantation, the preeminent international body in this field. Dr. Kormos has authored over 500 articles on heart and lung transplant, and is the most invited guest lecturer on this topic at medical conferences around the world.
Also, Gene Pearce, who is considered “the patriarch of organ transplant in the US.” Pearce is the founder and Chairman Emeritus of the United Network for Organ Sharing (UNOS), the quasi-governmental body that regulates organ transplantation in the US and controls the highly restricted “wait list.” His association with ALZM should help fast-track FDA approval.
Plus, Dr. Mark Zucker, a leader in heart transplants since 1987 and a major investigator in over 50 pharmaceutical and heart device trials. Dr. Zucker is on the editorial board as a reviewer for the Journal of the American College of Cardiology and has been named among Top Doctors in New York and New Jersey, Best Doctors in America, and America’s Top Physicians.
These leaders have enthusiastically backed ALZMand joined the company’s boards because they know this is a revolutionary technology that will transform the industry and SAVE HUNDREDS OF THOUSANDS OF LIVES!
And consider the dollars involved...
One heart transplant costs $1 million
A typical organ transplant costs between $200,000 and $800,000, and when you add in the immunosuppressant drugs that must be taken for life, the costs go up an additional $150,000 to $300,000 per patient (a big reason pharma companies will want to acquire ALZM). For example...
That’s right, 60,000 heart patients could benefit! At $1 million per operation!
But no one talks about such a number because, realistically, you can’t get the hearts. But ALZM has a way to dramatically expand the number of donor hearts, as you’ll see just ahead...
But first, you should know...
ALZM is starting with heart transplants for two reasons – first, it’s a BIG MARKET with a huge unmet need (currently only 27% success rate), and, second, it’s a life- or-death situation where ALZM can make a huge difference!
But soon enough, ALZM will branch out to lungs, kidneys, livers, pancreases, intestines, gall bladders, as well as to limbs, because the company’s “proprietary technology” can be adapted to all organs and limbs. In fact...
The Life Cradle™ System could be used by our military on the battlefield!
The Pentagon is excited about the prospects of reattaching limbs lost by soldiers in battle. The Life Cradle™ System can easily be included in a military unit’s support gear, and the injured soldier and his/her lost limb can be evacuated to the nearest medical facility for surgical repair.
Investors can feel proud to help our brave men and women in uniform, but this also saves taxpayer money because it eliminates the need for prosthetics and long-term therapy for our Vets who will now keep their own limbs! It’s a win, win!
Are you beginning to see why ALZM shares could quickly climb 10, 20, even 30 times higher? You don’t know the half of it...
advertisement, see disclaimer at bottom
The ALZM technology will soon rocket a $21 billion industry to $60 billion!
THIS IS KEY: Eventually, the ALZM technology should make it possible for everyone who needs a replacement organ to get one...
Today, over 100,000 people are on the organ-transplant waitlist, but if everybody who needed an organ could get one, the waitlist would grow to 300,000 patients – and that’s just in the US. The European and Asian markets are twice this size!
But what you MUST GRASP is that this $21 billion to $60 billion market expansion makes ALZM the most valuable company for acquisition by at least a dozen big medical device and pharmaceutical companies, including...
Especially note Johnson & Johnson, which has a medical-device division, plus a pharmaceutical division that includes immunology drugs. Remember, transplant patients must take expensive immunosuppressant drugs for life, and Johnson & Johnson can provide them.
Also note Cardinal Health, which has a medical-device division plus a drug distribution division. Analysts say the drug distribution industry in America is mature with very little room to grow. But ALZM would give Cardinal Health tremendous growth potential!
And in addition to the giants above, several smaller players, such as Hospira, Biomet or Invacare, could swoop in early and make the acquisition, since it would instantly put them atop a $6 billion (and growing) procurement market!
But enough BIG PICTURE stuff! Let me show you the amazing technology at the heart of the Life Cradle™ System and why it will transform the market!
Let’s start with the biggest problem ALZM solves – why the vast majority of organs, including 73% of hearts and 92% of lungs, are severely damaged or killed in transit.
And at this point, I’m going to switch exclusively to “heart transplants” since this is ALZM’s initial focus – a HUGE market at $1 million per operation, and also the most important in terms of emergency unmet need.
ALZM’s super advanced
technology replaces
primitive system
You may be surprise to learn that all donated hearts come from brain-dead but living persons. And it’s always an emotionally charged situation, with the family reluctant to “let go” of their loved one.
Unfortunately, the longer the wait, the more the heart deteriorates in the dying body. But a big advantage of the Life Cradle™ System is that it can actually resuscitate the heart in transit (more on this just ahead).
But once the family gives its approval, the transplant team leaps into action, harvesting the heart, flushing it with a purifying fluid, and then putting it in a plastic bag on ice in a picnic cooler.
And then it’s a “race for time.” And often the transplant surgeon flies by helicopter to the donor, makes the harvest, then flies in the same helicopter back to the transplant center for the operation, all of which is very costly.
But in spite of the big rush, a serious problem isn’t addressed...
Once the heart is harvested, it continues to metabolize, which means it needs oxygen and life-sustaining nutrients. And if it doesn’t get them it deteriorates and soon dies.
Unfortunately, the Igloo cooler provides nothing beyond ice and a “sealed environment.” And the ice damages the heart by freezing surface cells. And, what’s more, without proper nourishment and oxygen, the harvested heart builds up lactate, a biochemical byproduct of stress that causes heart damage.
The time factor is so critical that when an organ transplant center receives word a heart is available, the first question is, “How fast can you get it here?” If the answer is over “4 hours,” the heart will be rejected outright.
So the biggest limitation is geographic. Just how far can you travel in 1 to 2 hours before the heart is too far gone? And then...
When a donated heart arrives at the transplant center, the surgeon makes a physical examination and a “judgment call” on its likelihood of producing a successful outcome.
You can’t put a bad heart in somebody because you’ll kill them, so the surgeon’s “judgment call” is critical.
And yet he has no scientific data and no time for testing, as the“window of opportunity” to perform a successful transplant is fast closing on him.
ALZM completely solves this problem, providing a computer-generated “health status” report, and equally important, added time, if the surgeon wants to do further testing before proceeding.
Life-Cradle™ eliminates
tragic loss of donor organs
To drive this point home, recently 23 donor hearts became available in El Paso (western side of Texas), but since the transplant centers are in Dallas, Houston, and Austin (east side of Texas) not one arrived in time to be safely used.
That’s 23 lives that could’ve been saved but weren’t. And 23 donors that wanted to make a difference but didn’t. Sadly, all the hearts were wasted.
What’s more, when you have just 1 to 2 hours transit time, you don’t have the luxury of getting the best donor-to-recipient match. Many transplanted hearts are rejected by the recipient’s body because of a poor match, which can result in death, or the need for a second emergency transplant.
The worst part is that everything is rushed, and therefore highly risky!
A miracle that could soon make early ALZM shareholders rich! Let’s look at the revenue stream...
3-part Life-Cradle™ System provides
3 sources of continuous income
The Life-Cradle™ Perfusion System consists of 3 components, each one providing ALZM with a lucrative and steady income stream...
1.External Housing Unit: This piece maintains the ideal temperature, provides a completely sealed unit, contains space for the perfusion system to feed and oxygenate the heart, plus a computer-sensor system that monitors the heart’s health in transit (temperature, tissue health, toxin build-up, oxygen intake and more). The whole unit is small enough to be strapped into a regular passenger seat on commercial flights. And a single unit sells for about $50,000 and will last about 5 years with maintenance.
2.Internal Heart Container: This is the disposable (one-time-use- only) purified heart container, which fits inside the housing unit and contains a feeding tube to provide the nourishing and oxygenating perfusion fluid. This unit sells for about $15,000, and a new one must be used for each and every heart (or other organ or limb) transplant.
3.Perfusion Fluid: Think of “perfusion” as a cross between “force” and “infuse,” as the Life Cradle™ Perfusion System literally forces nourishing nutrients and oxygen into the heart (or other organ or limb) to keep it alive and healthy during transit. ALZM’s proprietary perfusion fluid sells for $300 per liter. And depending on the type of transplant and distance traveled, between 4 and 9 liters will be used, with an average cost of $2,000 per operation.
Here are the immediate benefits ALZM brings to the organ-transplant industry...
Greatly expands the geographical reach of donate dorgans!
Vastly improves donor-to-recipient organ matches!
Dramatically increases organ usage, ending tragic wastage!
High labor and transport costs due to emergency system!
No time for pre-op testing to help ensure a good outcome!
Significantly decreases mortality rates and SAVES LIVES!
Eliminates very costly emergency-based system!
Provides surge on with scientific health-status report, thus eliminating guesswork and improving results.
Dramatically expands the organ-transplant market, boosting revenues from $21 billion to $60 billion annually!
All investor please read this now! Shorts Scared Now!
http://www2.smallcapfortunes.com/alzm/index.html
1.The biggest names in “organ transplant”
are enthusiastically backing ALZM
2. No less than the illustrious former Wisconsin Governor and Health & Human Services Secretary, Tommy Thompson, is on the ALZM corporate board...
3. The Life Cradle™ System could be used by our military on the battlefield!
4. The ALZM technology will soon rocket a $21 billion industry to $60 billion!
5. Today, over 100,000 people are on the organ-transplant waitlist, but if everybody who needed an organ could get one, the waitlist would grow to 300,000 patients – and that’s just in the US. The European and Asian markets are twice this size!
6. But what you MUST GRASP is that this $21 billion to $60 billion market expansion makes ALZM the most valuable company for acquisition by at least a dozen big medical device and pharmaceutical companies, including...
Johnson & Johnson, GE HealthCare, Cardinal Health, Baxter, Siemens, Medtronic, Boston Scientific , etc.
7. ALZM is very conservatively projecting first year revenues at $250 million with 30% profit margins, but that’s just the tip of the iceberg. And the real value of the company is in the DRAMATIC $40 BILLION MARKET EXPANSION their technology makes possible.
15,000 to 20,000 share bocks being bought
GE BUYING ALZM RUMOR OR TRUTH. STOCK ALERT I RECEIVED STATED POSSIBILITY! I'M BUYING MORE ON THIS AND BESIDES ITS A GREAT LONG TERM STOCK TO HOLD!
PPS of ALZM is going to head MUCH HIGHER! Now these shares must be covered!
A short squeeze is going to happen soon! Many traders have sold short hundreds of thousands of shares in ALZM hoping that the stock would decline with the overall markets, but it hasn't!
Now these shares must be covered & when they will the PPS of ALZM is going to head MUCH HIGHER!
Continue watching ALZM & please review the news the company reported this morning.
I think we are going to see some major moves up very soon! A lot of strength and good sound fundamentals!
Buying ALZM today under $2 means you could watch a $5,000 investment blossom into $300,000 – $10,000 explode into $600,000 – all before July 1st, 2011!
When it comes to organ transplants, the difference between life and death is seconds, not minutes. ALZM puts that precious time back in doctor’s hands by extending the organ viability window by 700%!
This breakthrough could literally save millions of lives...
but it could also make us incredibly wealthy in the process!
Hello Fellow Player,
Not since penicillin has a medical discovery saved so many lives in such a short period of time…
ALZM is shocking the medical community with its JUST RELEASED revolutionary, life-saving breakthrough.
You see, in over 40 years, there hasn’t been any significant advance in organ transportation… until now.
Leading medical experts now agree, this unique, patented, PROVEN game-changing technology could save anywhere between 287k to 350k lives each year…
And that’s in the United States alone.
When It Comes To Organ Transplants, The Difference
Between Life And Death IsSeconds, Not Minutes.
ALZM Puts That PreciousTime Back In Doctor’s Hands
Allezoe Medical (ALZM) has discovered a way to not only safely transport organs to the patients in dire need of them, but they’ve figured out a way to keep the viability window open another 17-21 hours longer than current methods!
Words cannot express how big this breakthrough is.
To get a true understanding of the magnitude of this discovery you have to know a few facts…
First of which, is the fact that of all the people on a transplant waitlist, only 35% of them live long enough to receive their second chance at life, mostly due to the state and health that the organ arrives at.
This is a staggering statistic.
Which is why experts are predicting such big things for ALZM…
Because not only can they improve the state of health of many of these organs during transport, but by offering an wider viability window, expanding that 35% success rate up to 80%!
What this means is that the lives of potentially Millions of people can be saved with ALZM’s technology.
That’s Why It’s So Urgent You Read My Hot-Off-The-Press Report NOW. In It, You’ll See Why You Could Make
3,000% In The Coming Weeks. Every $5,000 Invested
Today, Could Be WorthA Staggering $300k By July 1st!
The importance of this innovation is apparent and obvious…
But it can also be just as lucrative to investors who are there from the very beginning as it is to those in need of the service that ALZM provides.
In fact, 2,000% - 3,000% gains may be on the low end of the spectrum when all is said and done…
Especially if a high-priced and aggressive bidding war breaks out among many of medicines biggest names like Johnson and Johnson , GE Healthcare and Siemans... once they catch wind of the profit potential that ALZM is offering.
I’ve just finished an in-depth, detailed report that will give you all the facts on why this company could be the best and biggest move of your financial career. Get the whole story HERE.
Get the whole story HERE.
To Your Future Wealth,
Eric Dickson
Editor, Breakaway Stocks
I picked up 4000 shares today....love what I am reading and the charts look great....this one is going to go up!!